You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

300 Results
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    niraparib - For the maintenance treatment of newly diagnosed or recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, according to clinical criteria
Mar 2025
Cette plateforme contient des outils et des ressources pour les prestataires de soins primaires, les colposcopistes et d’autres professionnels de la...
Dans tout l’Ontario, les centres de cancérologie, les hôpitaux et les cliniques proposent une vaste gamme de services de dépistage, de diagnostic et...
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Updated
Mar 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
Updated
Mar 2025
Regimen
Intent: Adjuvant
Updated
Mar 2025
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Updated
Mar 2025
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma
Updated
Mar 2025
Regimen
Intent: Palliative
Mar 2025
Regimen
Intent: Palliative
Mar 2025
Guidelines and Advice
Status: In-Review
ID: 19-4
May 2015

Pages